The Centre for Process Innovation (CPI) has announced that the new flagship National Biologics Manufacturing Centre (part of the UK Governments Strategy for Life Science) will be located in Darlington. Great news for strengthening the UK’s capability in biologics and developing a competitive edge within the growing global biopharmaceutical market!
Darlington was chosen based on accessibility with good transport links, proximity to existing pharmaceutical companies and universities in the region, and growth opportunities within the Tees Valley Enterprise Zone. The new centre, which forms part of CPI, will help companies of all sizes in the biologics market to develop, prove, demonstrate, scale up and ultimately commercialise new biologics process technologies.
Read the full story here.
Darlington was chosen based on accessibility with good transport links, proximity to existing pharmaceutical companies and universities in the region, and growth opportunities within the Tees Valley Enterprise Zone. The new centre, which forms part of CPI, will help companies of all sizes in the biologics market to develop, prove, demonstrate, scale up and ultimately commercialise new biologics process technologies.
Read the full story here.
RSS Feed
